SI2197900T1 - Mutantni dvojno ciklizirani receptorski peptidi ki inhibirajo protitelesa beta adrenoceptorja - Google Patents

Mutantni dvojno ciklizirani receptorski peptidi ki inhibirajo protitelesa beta adrenoceptorja

Info

Publication number
SI2197900T1
SI2197900T1 SI200830783T SI200830783T SI2197900T1 SI 2197900 T1 SI2197900 T1 SI 2197900T1 SI 200830783 T SI200830783 T SI 200830783T SI 200830783 T SI200830783 T SI 200830783T SI 2197900 T1 SI2197900 T1 SI 2197900T1
Authority
SI
Slovenia
Prior art keywords
receptor peptides
inhibiting beta
peptides inhibiting
mutant double
cyclized
Prior art date
Application number
SI200830783T
Other languages
English (en)
Slovenian (sl)
Inventor
Roland Jahns
Valerie Jahns
Martin Lohse
Viacheslav Nikolaev
Original Assignee
Julius Maximilians Uni Wurzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Uni Wurzburg filed Critical Julius Maximilians Uni Wurzburg
Publication of SI2197900T1 publication Critical patent/SI2197900T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
SI200830783T 2007-08-24 2008-08-22 Mutantni dvojno ciklizirani receptorski peptidi ki inhibirajo protitelesa beta adrenoceptorja SI2197900T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07016637 2007-08-24
EP08801676A EP2197900B9 (en) 2007-08-24 2008-08-22 Mutant double cyclized receptor peptides inhibiting beta 1-adrenoceptor antibodies
PCT/EP2008/006932 WO2009027063A2 (en) 2007-08-24 2008-08-22 MUTANT DOUBLE CYCLIZED RECEPTOR PEPTIDES INHIBITING β1-ADRENOCEPTOR ANTIBODIES

Publications (1)

Publication Number Publication Date
SI2197900T1 true SI2197900T1 (sl) 2012-11-30

Family

ID=40130559

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200830783T SI2197900T1 (sl) 2007-08-24 2008-08-22 Mutantni dvojno ciklizirani receptorski peptidi ki inhibirajo protitelesa beta adrenoceptorja

Country Status (13)

Country Link
US (1) US9062095B2 (https=)
EP (3) EP2197900B9 (https=)
JP (3) JP5248610B2 (https=)
CN (2) CN101835793B (https=)
AU (1) AU2008291296B2 (https=)
CA (1) CA2697108C (https=)
DK (1) DK2197900T3 (https=)
ES (1) ES2391358T3 (https=)
HR (1) HRP20120827T1 (https=)
PL (1) PL2197900T3 (https=)
PT (1) PT2197900E (https=)
SI (1) SI2197900T1 (https=)
WO (1) WO2009027063A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835793B (zh) * 2007-08-24 2014-04-23 乌利班-马克西姆利安大学 抑制β1-肾上腺素受体抗体的突变双环化受体肽
MX2011007882A (es) * 2009-01-27 2011-11-04 Univ Wuerzburg J Maximilians HOMOLOGOS-PEPTIDO NOVEDOSO PARA INHIBIR ANTICUERPOS ß1- ADRENOCEPTORES.
DE102010018878B4 (de) 2009-04-30 2013-09-26 Julius-Maximilians-Universität Würzburg Neue Zell-Linie zur Fluoreszenz-basierten Detektion von funktionell aktiven Antikörpern und Autoantikörpern gegen den Beta1-adrenergen Rezeptor
EP2402016A1 (en) * 2010-06-29 2012-01-04 Charité - Universitätsmedizin Berlin Aptamers that inhibit interaction between antibody and 1st or 2nd extracellular loop of human beta-1-adrenergic receptor
JP2014519329A (ja) 2011-06-10 2014-08-14 コリムン ゲーエムベーハー ヒトβ１−アドレノレセプター（β１−ＡＲ）に対する結合化合物および自己−抗β１−ＡＲ抗体の測定におけるその使用
MX356107B (es) 2012-02-16 2018-05-15 Atyr Pharma Inc Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
CN105378075B (zh) 2013-03-15 2022-04-05 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
JPWO2015022953A1 (ja) * 2013-08-14 2017-03-02 国立大学法人 長崎大学 血液脳関門障害改善剤
CN110536694A (zh) 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
CN108218963B (zh) * 2018-01-19 2020-10-13 首都医科大学 一种环肽及其制备方法和用途
TW202100556A (zh) * 2019-03-14 2021-01-01 美商建南德克公司 使用her2 t細胞依賴性雙特異性抗體之治療
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
IL301332A (en) * 2020-09-23 2023-05-01 Ablevia Biotech Gmbh Compound for the prevention or treatment of autoantibody-mediated conditions
CN112266330B (zh) * 2020-10-15 2023-02-24 长沙博源医疗科技有限公司 一种甲氧基肾上腺素衍生物、免疫原、抗甲氧基肾上腺素特异性抗体及其制备方法与应用
EP4392430A4 (en) 2021-08-27 2026-04-29 Univ Yale Molecular degraders of extracellular proteins
JP2023117892A (ja) * 2022-02-14 2023-08-24 公益財団法人 鷹揚郷 ヘプシジン結合ペプチド
CN120647762B (zh) * 2025-06-16 2026-01-23 首都医科大学附属北京友谊医院 一种抗β1-AR-ECII抗体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
KR20020047177A (ko) * 1999-09-21 2002-06-21 아피나 이문테히닉 게엠베하 확장성 심근질환을 유발하는 자동항체를 제거하기 위한펩티드
CA2389524A1 (en) * 1999-11-05 2001-05-17 The Regents Of The University Of California Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
JP4541490B2 (ja) * 2000-04-07 2010-09-08 株式会社カネカ 拡張型心筋症用吸着体
WO2001083693A2 (en) 2000-04-28 2001-11-08 Glaxo Group Limited Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
CN1988914A (zh) * 2001-08-23 2007-06-27 西兰制药公司 胞间通讯易化化合物的新医学用途
US7041790B2 (en) * 2002-03-26 2006-05-09 Dyax Corp. Fibrinogen binding moieties
WO2004069863A2 (en) * 2003-02-04 2004-08-19 New York University Constrained hiv v3 loop peptides as immunogens and receptor antagonists
EP1536020A1 (en) 2003-11-26 2005-06-01 Bayerische Julius-Maximilians-Universität Würzburg Means and methods for optical determination of cAMP in vitro and in vivo
EP1866335B1 (en) * 2005-03-31 2013-10-16 Julius-Maximilians-Universität Würzburg MEANS FOR THE INHIBITION OF ANTI- ß1-ADRENERGIC RECEPTOR ANTIBODIES
CN101835793B (zh) * 2007-08-24 2014-04-23 乌利班-马克西姆利安大学 抑制β1-肾上腺素受体抗体的突变双环化受体肽

Also Published As

Publication number Publication date
AU2008291296B2 (en) 2014-02-06
EP2559698B1 (en) 2014-11-12
JP2010536356A (ja) 2010-12-02
CN103992406A (zh) 2014-08-20
WO2009027063A3 (en) 2009-07-23
CA2697108A1 (en) 2009-03-05
CN101835793A (zh) 2010-09-15
ES2391358T3 (es) 2012-11-23
WO2009027063A2 (en) 2009-03-05
JP2013176369A (ja) 2013-09-09
CN101835793B (zh) 2014-04-23
EP2559698A3 (en) 2013-03-06
EP2559698A2 (en) 2013-02-20
EP2497777A2 (en) 2012-09-12
PL2197900T3 (pl) 2012-12-31
HK1176363A1 (en) 2013-07-26
EP2497777A3 (en) 2012-10-10
JP5248610B2 (ja) 2013-07-31
US9062095B2 (en) 2015-06-23
EP2197900A2 (en) 2010-06-23
JP2013138679A (ja) 2013-07-18
PT2197900E (pt) 2012-10-24
DK2197900T3 (da) 2012-10-22
HRP20120827T1 (hr) 2012-11-30
CA2697108C (en) 2018-05-22
EP2197900B1 (en) 2012-08-01
AU2008291296A1 (en) 2009-03-05
EP2197900B9 (en) 2013-01-09
US20100209445A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
SI2197900T1 (sl) Mutantni dvojno ciklizirani receptorski peptidi ki inhibirajo protitelesa beta adrenoceptorja
EP2184278A4 (en) P2X4 RECEIVER ANTAGONIST
PT1981902E (pt) Antagonistas dos recetores nogo
IL204536A0 (en) Anti - il -6 receptor antibody
EP2058304A4 (en) P2X4 RECEPTOR ANTAGONIST
ZA201001874B (en) Nmda receptor antagonists for neuroprotection
EP2099454A4 (en) AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS
ZA201001597B (en) Octahydropentalene compounds as chemokine receptor antagonists
EP2129654A4 (en) NEW ANTAGONISTS OF THE GLUCAGON RECEPTOR
IL212551A0 (en) Cxcr4 receptor compounds
ZA200904150B (en) Progesterone receptor antagonists
IL187424A0 (en) C5a RECEPTOR ANTAGONISTS
IL205356A0 (en) Novel glucocorticoid receptor agonists
IL198241A0 (en) Pyrazoline compounds as mineralocorticoid receptor antagonists
IL184278A0 (en) C5a RECEPTOR ANTAGONISTS
ZA201001125B (en) Pyrrolidine Aryl-Ether as NK3 receptor antagonists
ZA201000676B (en) Pyrrolidine aryl-ether as NK3 receptor antagonists
EP2191830A4 (en) SOLID PREPARATION COMPRISING A NPYY5 RECEPTOR ANTAGONIST
IL198542A0 (en) 2-aminoquinolines as 5-ht(5a)receptor antagonists
EP2153736A4 (en) NEW LEUKOTRIEN RECEPTOR ANTAGONIST
IL200380A0 (en) Mineralcorticoid receptor antagonists for the treatment of endometriosis
ZA200903499B (en) Indoles which act as via receptor antagonists
EP2478001A4 (en) BENEFICIAL PEPTIDE COMPOUNDS OF MU OPIACEOUS RECEPTOR
EP2229400A4 (en) ADVANTAGEOUS SALTS OF MU-OPIOD RECEPTOR PEPTIDES
IL202454A0 (en) Urotensin ii receptor antagonists